Linagliptin/Metformin Hexal

Linagliptin, the active ingredient in Linagliptin/Metformin Hexal, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It helps control blood glucose in adults with type 2 diabetes when used with diet and exercise. Metformin hydrochloride, also present, is a biguanide that reduces hepatic glucose production and improves insulin sensitivity.

GNH USA supplies Linagliptin/Metformin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin/Metformin Hexal is indicated for the management of type 2 diabetes mellitus, acting on glucose metabolism pathways.

- Type 2 diabetes mellitus: improves overall glycaemic control when combined with diet and exercise. - Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower HbA1c. - Adjunct to other oral antidiabetics: can be combined with sulfonylureas or insulin for additional glucose lowering.

Adverse reactions may occur with Linagliptin/Metformin Hexal and are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools, usually transient. - Headache: mild tension‑type headache. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or hepatitis.

Before prescribing Linagliptin/Metformin Hexal, clinicians should consider several safety aspects.

- Renal function assessment: evaluate eGFR, especially for metformin component. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Drug interaction monitoring: review concomitant medications that affect glucose or renal clearance. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Linagliptin/Metformin Hexal may interact with other medicines; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin before imaging. - Insulin secretagogues (e.g., sulfonylureas): increase risk of severe hypoglycaemia. - Rifampin: reduces linagliptin exposure, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: can mask hypoglycaemia symptoms. - NSAIDs or diuretics: may impair renal function, affecting metformin clearance. - ACE inhibitors or ARBs: monitor renal function and electrolytes when combined.